INVIVYD, INC. Costs and Expenses
INVIVYD, INC. (IVVD) reported Costs and Expenses of $60.10 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:CostsAndExpenses · last filed 2026-08-13
- INVIVYD, INC. costs and expenses for the quarter ending 2026-06-30 was $60.10M, a 123.89% increase year-over-year.
- INVIVYD, INC. costs and expenses for the quarter ending 2026-03-31 was $56.88M, a 101.52% increase year-over-year.
- INVIVYD, INC. costs and expenses for the quarter ending 2025-12-31 was $29.76M, a 9.95% decline year-over-year.
- INVIVYD, INC. costs and expenses for the quarter ending 2025-09-30 was $24.15M, a 66.27% decline year-over-year.
- INVIVYD, INC. costs and expenses for fiscal 2025 was $108.99M, a 46.12% decline from fiscal 2024.
- INVIVYD, INC. costs and expenses for fiscal 2024 was $202.26M, a 4.93% decline from fiscal 2023.
- INVIVYD, INC. costs and expenses for fiscal 2023 was $212.76M.
| Period end | Costs and Expenses 3 month | Costs and Expenses 6 month | Costs and Expenses 9 month | Costs and Expenses 12 month |
|---|---|---|---|---|
| 2026-06-30 | $60.10M 10-Q · filed 2026-08-13 | $116.98M 10-Q · filed 2026-08-13 | $146.75M derived: sum of 3 quarters · filed 2026-08-13 | $170.90M derived: sum of 4 quarters · filed 2026-08-13 |
| 2026-03-31 | $56.88M 10-Q · filed 2026-05-14 | $86.64M derived: sum of 2 quarters · filed 2026-05-14 | $110.79M derived: sum of 3 quarters · filed 2026-05-14 | $137.64M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-12-31 | $29.76M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | $53.91M derived: sum of 2 quarters · filed 2026-03-05 | $80.76M derived: sum of 3 quarters · filed 2026-08-13 | $108.99M 10-K · filed 2026-03-05 |
| 2025-09-30 | $24.15M 10-Q · filed 2025-11-06 | $51.00M derived: sum of 2 quarters · filed 2026-08-13 | $79.22M 10-Q · filed 2025-11-06 | $112.27M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-06-30 | $26.85M 10-Q · filed 2026-08-13 | $55.07M 10-Q · filed 2026-08-13 | $88.12M derived: sum of 3 quarters · filed 2026-08-13 | $159.73M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-03-31 | $28.23M 10-Q · filed 2026-05-14 | $61.27M derived: sum of 2 quarters · filed 2026-05-14 | $132.89M derived: sum of 3 quarters · filed 2026-05-14 | $184.40M derived: sum of 4 quarters · filed 2026-05-14 |
| 2024-12-31 | $33.05M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | $104.66M derived: sum of 2 quarters · filed 2026-03-05 | $156.17M derived: sum of 3 quarters · filed 2026-03-05 | $202.26M 10-K · filed 2026-03-05 |
| 2024-09-30 | $71.61M 10-Q · filed 2025-11-06 | $123.12M derived: sum of 2 quarters · filed 2025-11-06 | $169.21M 10-Q · filed 2025-11-06 | $245.96M derived: sum of 4 quarters · filed 2025-11-06 |
| 2024-06-30 | $51.51M 10-Q · filed 2025-08-14 | $97.60M 10-Q · filed 2025-08-14 | $174.35M derived: sum of 3 quarters · filed 2025-08-14 | $217.41M derived: sum of 4 quarters · filed 2025-08-14 |
| 2024-03-31 | $46.09M 10-Q · filed 2025-05-15 | $122.84M derived: sum of 2 quarters · filed 2025-05-15 | $165.90M derived: sum of 3 quarters · filed 2025-05-15 | $219.78M derived: sum of 4 quarters · filed 2025-05-15 |
| 2023-12-31 | $76.75M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-20 | $119.81M derived: sum of 2 quarters · filed 2025-03-20 | $173.69M derived: sum of 3 quarters · filed 2025-03-20 | $212.76M 10-K · filed 2025-03-20 |
| 2023-09-30 | $43.06M 10-Q · filed 2024-11-14 | $96.94M derived: sum of 2 quarters · filed 2024-11-14 | $136.01M 10-Q · filed 2024-11-14 | |
| 2023-06-30 | $53.88M 10-Q · filed 2024-08-14 | $92.95M 10-Q · filed 2024-08-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |
| FATE THERAPEUTICS INC (FATE) | United States | $0.280B | -2.51 |
| Liminatus Pharma, Inc. (LIMN) | United States | $0.282B | |
| Inhibikase Therapeutics, Inc. (IKT) | United States | $0.296B | -4.44 |
| X4 Pharmaceuticals, Inc (XFOR) | United States | $0.297B | -4.99 |
| Lineage Cell Therapeutics, Inc. (LCTX) | United States | $0.241B | -10.35 |
| Aligos Therapeutics, Inc. (ALGS) | United States | $0.238B | -0.47 |
| SAB Biotherapeutics, Inc. (SABS) | United States | $0.306B | -25.49 |